Editas Stock Rises on Updated Data From SCD Study of Reni-Cel [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
disease (SCD) study of its lead candidate, renizgamglogene autogedtemcel (reni-cel; formerly known as EDIT-301). The data readout is from 28 SCD patients who have been treated with reni-cel in the phase I/II/III RUBY study. Editas is scheduled to present detailed results at the upcoming American Society of Hematology Annual Meeting in San Diego, CA. The company is focused on developing reni-cel as a potential one-time, durable gene editing medicine to treat SCD as well as transfusion-dependent beta thalassemia (TDT). This data readout follows the June 2024 press releases, when the company last reported new positive data from the phase I/II/III RUBY study of reni-cel in 18 patients with SCD and an early-to-mid-stage of the same in seven patients with TDT. Per the latest data readout from the RUBY study, 27 out of 28 patients remained free of vaso-occlusive events. Notably, patients experienced early normalization of total hemoglobin (Hb) levels, averaging 13.8 g/dL, and significant
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Evercore ISI from $7.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Royal Bank of Canada from $5.00 to $4.00. They now have a "sector perform" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Barclays PLC from $5.00 to $3.00. They now have an "equal weight" rating on the stock.MarketBeat
- Editas Medicine, Inc. (NASDAQ: EDIT) had its "neutral" rating re-affirmed by analysts at Chardan Capital.MarketBeat
EDIT
Earnings
- 11/4/24 - Beat
EDIT
Sec Filings
- 12/17/24 - Form 8-K
- 12/12/24 - Form 8-K
- 12/10/24 - Form 8-K
- EDIT's page on the SEC website